COMPOUND WITH CONFIDENCE: PCCA Membership, $795/month.
Stay current on PCCA news and events, market trends, and all things compounding!
Compounding pharmacists are committed to helping their patients live healthier, better lives —and key to this is ensuring their patients have continuing access to lawfully prescribed, personalized medications tailored to their individual needs.
At PCCA, we proudly partner with our members to support the unique needs of your patients and prescribers through the science of compounding. We also recognize the importance of effectively communicating the value of compounded medications. As we navigate this path, it is crucial to adhere to established guidelines and embrace best practices in promoting your compounded medications.
On November 1, 2023, revisions to USP Chapter 795 and Chapter 797 became official and made USP 800 compendially applicable and potentially enforceable. However, other regulatory agencies — including state boards of pharmacy and the FDA — may impact whether USP 800 is enforceable in your pharmacy.
ThinkNext: International Seminar 2023 (ThinkNext: ISTX23) was a huge success, attended by more than 400 global participants. We’re reviewing the pearls — highlights of key takeaways — from the event to rekindle memories and, for those who missed attending, inspire your participation next year.
Due to pending USP updates that are effective on November 1, 2023, we’re reposting our January Blog, which reviews how a modular compounding cleanroom can meet evolving regulatory requirements and standards.
Review the criteria for selecting an FDA-approved API to safeguard your patients and your compounding pharmacy.
Read why Kayla Valigura, PharmD candidate and 2022 PCCA Institute Scholarship award winner, wants your help in acting on something near and dear to her heart.
FDA’s Guidance for Industry (GFI) on compounding for animals using bulk drug substances will be used in FDA inspections starting on April 1, 2023. Read the top five potential impacts on compounding for animal patients.
Matt Martin, PharmD, BCSCP, PCCA Director of Clinical Services, reviews USP 797revisions and impacts on compounding pharmacies in the fourth of a four-part series.
Matt Martin, PharmD, BCSCP, PCCA Director of Clinical Services, reviews USP 797 revisions and impacts on compounding pharmacies in the third of a four-part series.